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Research
Florida red tides are a manifestation of the 
larger growing environmental issue of harm-
ful algal blooms (HABs) (Erdner et al. 2008; 
Van Dolah 2000). HABs are blooms of micro-
algae in aquatic environments, causing harm to 
humans and other animals, particularly by the 
production of potent natural toxins. Florida 
red tide is caused by the marine dinoflagel-
late Karenia brevis, which produces the potent 
neuro  toxins brevetoxins. These toxins cause 
the death of millions of fish annually in the 
Gulf of Mexico, as well as morbidity and mor-
tality among marine mammals and sea birds. 
Exposure to seafood contaminated by breve-
toxins is associated with neurotoxic shellfish 
poisoning in humans, whereas the aerosols of 
the Florida red tide have been reported to cause 
respiratory irritation in persons recreating and 
working in coastal communities during active 
blooms with onshore winds (Backer et al. 2003, 
2005; Fleming et al. 2005a, 2005b, 2007; 
Watkins et al. 2008; Zaias et al., in press). 
Our prior research demonstrated that 
persons with a physician diagnosis of asthma 
experience a statistically significant change in 
their respiratory symptoms and pulmonary 
function after a 1-hr visit to the beach during 
a documented Florida red tide; these changes 
are not seen when the same individuals visit 
the beach for 1 hr during a non-Florida red 
tide period (Fleming et al. 2007; Milian et al. 
2007). As part of our research, at the same time 
we collected symptom and pulmonary function 
data before and after the beach exposure for 
each individual subject, we collected substantial 
ambient samples including water for K. brevis 
cell counts and brevetoxin concentrations; 
ambient aerosol samples for brevetoxin concen-
trations and aerosol particle size; and individual 
personal air samples for brevetoxin concen-
trations (Cheng et al. 2005a, 2005b, 2005c; 
Naar et al. 2002; Pierce et al. 2003). In the 
present study we investigated for the first time 
which of the meas  ures of brevetoxin concen-
trations in ambient samples were most closely 
associated with health effects and whether there 
were dose–response relationships between these 
ambient measurements and health outcomes.
Methods
An interdisciplinary team of researchers from 
federal, state, private, and local organizations 
have been evaluating aerosolized K. brevis red 
tide brevetoxin exposures and their possible 
acute and chronic adverse health effects in 
humans and animals. The study has been 
approved by the participating institutional 
review boards. The study location was Siesta 
Beach (Sarasota, FL), where prolonged Florida 
red tides lasting months have become almost 
an annual event. Although the asthmatic cohort 
has been studied since 2003, the data used in 
this analysis were from Florida red tide exposure 
periods in March 2005 and September 2006.
The study participants consisted of an 
open cohort of asthmatics with the following 
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Ba c k g r o u n d: In previous studies we demonstrated statistically significant changes in reported 
symptoms for lifeguards, general beach goers, and persons with asthma, as well as statistically sig-
nificant changes in pulmonary function tests (PFTs) in asthmatics, after exposure to brevetoxins in 
Florida red tide (Karenia brevis bloom) aerosols. 
oBjectives: In this study we explored the use of different methods of intensive ambient and per-
sonal air monitoring to characterize these exposures to predict self-reported health effects in our 
asthmatic study population. 
Me t h o d s : We evaluated health effects in 87 subjects with asthma before and after 1 hr of exposure 
to Florida red tide aerosols and assessed for aerosolized brevetoxin exposure using personal and 
ambient samplers. 
re s u l t s: After only 1 hr of exposure to Florida red tide aerosols containing brevetoxin concentra-
tions > 57 ng/m3, asthmatics had statistically significant increases in self-reported respiratory symp-
toms and total symptom scores. However, we did not see the expected corresponding changes in 
PFT results. Significant increases in self-reported symptoms were also observed for those not using 
asthma medication and those living ≥ 1 mile from the coast.
co n c l u s i o n s: These results provide additional evidence of health effects in asthmatics from ambi-
ent exposure to aerosols containing very low concentrations of brevetoxins, possibly at the lower 
threshold for inducing a biologic response (i.e., toxicity). Consistent with the literature describing 
self-reported symptoms as an accurate measure of asthmatic distress, our results suggest that self-re-
ported symptoms are a valuable measure of the extent of health effects from exposure to aerosolized 
brevetoxins in asthmatic populations. 
key w o r d s : asthma, brevetoxins, harmful algal blooms (HABs), Karenia brevis, red tides, sensi-
tive populations, spirometry. Environ Health Perspect 117:1095–1100 (2009).  doi:10.1289/
ehp.0900673 available via http://dx.doi.org/ [Online 13 April 2009]Fleming et al.
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characteristics: a self-report of physician-
  diagnosed asthma; ≥ 12 years of age, history 
of smoking ≤ 10 years; able to walk on the 
beach continuously for at least 30 min; and at 
least 6 months residence in the Sarasota area. 
For our study, participants spent ≥ 1 hr at the 
beach in areas with on  going ambient moni-
toring. During this time, they could return 
from the beach at any time if they felt symp-
tomatic, and all participants were encouraged 
to use any personal medications as needed 
before, during, and after the study period. 
Participants were asked not to change their 
daily asthma management regime on the day 
of the study. 
After obtaining informed consent, we col-
lected detailed baseline information for all 
subjects (including their medical history and 
possible confounders) in a baseline question-
naire. Each subject participated in at least 
one evalua  tion during an active K. brevis 
bloom (exposure period) and in one evalu-
ation during a period when there was not a 
bloom (non  exposure period), although only 
the exposure period data were used for the 
analysis. Both evaluations included pre  beach 
and post  beach questionnaires, nasal swab 
sampling, and spirometry. The pre  beach and 
post  beach questionnaires collected informa-
tion on recent medical history and medica-
tion use, as well as symptoms and possible 
confounders (e.g., smoking). 
Each study participant carried an IOM 
personal air monitor (SKC Inc., Eighty Four, 
PA) during their 1 hr of beach exposure. Based 
on the results of ambient monitoring, the per-
sonal monitoring for brevetoxins is important, 
as the aerosols can vary widely within a stretch 
of beach, due to wind gusts and direction, the 
patchy nature of K. brevis blooms, and varia-
tion between participants depending on where 
and when she/he walked on the beach during 
an active Florida red tide bloom (Cheng et al. 
2005a, 2005b, 2005c).
Pulmonary function testing was per-
formed according to National Institute for 
Occupational Safety and Health (NIOSH) 
standards (NIOSH 1997) using a portable 
OMI2000 10-L dry rolling seal volume 
spirometer (Occupational Marketing, Inc., 
Houston, TX) before and after 1-hr beach 
exposure. The spirometry values were forced 
expiratory volume in 1 sec (FEV1); the average 
rate of flow during the middle half of a forced 
vital capacity (FVC) maneuver (FEF25–75); 
peak expiratory flow (PEF), and FVC. Only 
data conforming to the standard guidelines 
for collection and interpretation of spirometry 
measurements were accepted, and all study 
participants had ≥ 3 reproducible spirograms 
before and after visiting the beach (Fleming 
et al. 2007; NIOSH 1997).
Ambient monitoring. For ambient moni-
toring, a portable, self-contained weather 
station near a high-volume air particle impac-
tor and the ambient air samplers was used to 
monitor the air temperature, relative humid-
ity, wind speed, and direction, as described 
previously (Cheng et al. 2005a, 2005b, 2005c; 
Naar et al. 2002; Pierce et al. 2003). Water 
samples were collected twice daily in 1-L glass 
bottles from the surf zone adjacent to the 
high-volume air sampler locations. The water 
samples were analyzed for K. brevis cell counts 
and for brevetoxin concentrations using both 
the brevetoxin enzyme-linked immunosor-
bent assay (ELISA) and liquid chromatog-
raphy-mass spectroscopy (LC-MS) analysis 
(Fleming et al. 2007; Naar et al. 2002; Pierce 
et al. 2003). 
Air samples for toxin and particulate size 
were collected using two types of high-volume 
samplers (high-volume filter and high-volume 
air particle impactors equipped to capture aero-
sol particles by size) and a personal sampler 
of the subject breathing zone. We measured 
brevetoxins by the high-volume sampler and 
the personal sampler. For the high-volume filter 
samplers, six 4-hr air filter samples and eight 
1-hr air filter samples were measured at a sam-
pling flow rate between 1.6 and 2.0 m3/min. 
The 1-hr personal exposure of each participant 
was measured using an individual personal air 
sampler placed near the breathing zone; the 
sampling flow rate for the personal samplers 
was 9-L/min (Cheng YS, personal commu-
nication). For the personal samples, we used 
only the brevetoxin ELISA because it had a 
lower limit of detection (LOD) than LC-MS, 
which is important given the low flow rate of 
the personal air sampler and the small size of 
the filter paper to be analyzed for breve  toxins. 
The ambient samples could be analyzed by both 
LC-MS and brevetoxin ELISA because the flow 
rate of the ambient air sampler was substantially 
higher and the filter paper was larger.
The brevetoxin ELISA measures any sub-
stance (parent toxins and toxins derivatives/
metabolites) containing the brevetoxin type 2 
backbone structure. As such, the reported 
concentration represents the total amount 
of brevetoxin-like compounds present in the 
sample and may also include toxins and/or 
derivatives that have not yet been chemically 
described. The LC-MS levels reported in this 
study represent only the sum of the concentra-
tion of five specific breve  toxins that could be 
present in a given sample (PbTx-1, PbTx-2, 
PbTx-3, PbTx-9, and PbTx-3 42-carboxylic 
acid). During the 2005 and 2006 exposure 
periods, the LOD for individual brevetoxins 
in sea  water was 0.03 µg/L using LC-MS and 
0.6 ng/sample using the brevetoxin ELISA for 
all brevetoxins. The LOD for the LC-MS anal-
ysis of the ambient air samples was 0.01 ng/m3 
for individual brevetoxins; the ELISA LOD 
for both the ambient and personal samples was 
0.6 ng/sample for all brevetoxins combined.
Exposure and health assessment. In previ-
ous analyses involving the asthmatic cohort, 
“exposure” was defined as spending 1 hr 
on the beach during a study day when a) 
K. brevis cells above background levels (i.e., 
> 5,000 cells/L) and brevetoxins were detected 
by LC-MS and ELISA in the water, and b) 
brevetoxins were detected in the ambient air 
monitors by LC-MS and ELISA (Fleming 
et al. 2005b, 2007; Milian et al. 2007). 
However, no attempt was made previously 
to assign individual exposure levels or to use 
the personal air sampler data. In this analysis, 
each subject who had participated in a study 
during an active Florida red tide was assigned 
a) the ELISA brevetoxin level from their indi-
vidual personal air sampler (personal ELISA); 
b) the ELISA brevetoxin level from the hourly 
ambient air sampler (ambient ELISA) that 
corresponded to their individual beach walk 
time; and c) the LC-MS brevetoxin level from 
the hourly ambient air sampler (ambient 
LC-MS) that corresponded to their individual 
beach walk time. The ambient sampler breve-
toxin concentrations were calculated from the 
hourly samples corresponding to the sampling 
time of each personal sample. When a per-
sonal sample was taken during a portion of 
two hourly ambient samples, the correspond-
ing ambient concentration was calculated by 
multiplying the hourly sample with the frac-
tion of time the personal sample was taken 
during each of the particular hourly samples 
and then summing the two concentrations.
We asked questions about the presence of 
symptoms consistent with asthma (i.e., eye, 
Table 1. Demographics of 87 study participants with physician-diagnosed asthma.
Variable  No. (%)
Age [years; mean ± SD (range)]  44.9 ± 19.2 (12.0–79.0)
Female  52 (59.8)
White  85 (97.7)
Hispanic  1 (1.2)
Years with diagnosis (mean ± SD)  16.5 ± 25.2
Currently use asthma medicationsa   68 (88.3)
Positive history of Florida red tide symptoms with exposure  77 (90.6)
Current smoker   8 (12.3)
Hospitalized ≥ 1 time in past year from respiratory causes  11 (13.1)
Used medicationsa within 12 hr before study exposureb   30 (34.5)
Live ≥ 1 mile from coastb   55 (63.2)
aAsthma medications predominantly beta2 agonists. bAt time of ambient LC-MS brevetoxin measurement. Asthma and brevetoxin exposure
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nose, and throat irritation, cough, wheeze, 
chest tightness, and shortness of breath) before 
and after spending 1 hr on the beach. If the 
participant reported any symptom, they were 
asked if they experienced it as mild, moder-
ate, or severe. We analyzed the symptom data 
in two ways. First, the number of persons not 
reporting a symptom before going on the beach 
but reporting the particular symptom after 
exposure was counted as being symptomatic 
from exposure (Fleming et al. 2005b, 2007). 
Second, for those individuals reporting any 
respiratory symptom, we devised a respiratory 
symptom intensity score based on the sum of 
all respiratory symptoms with their individual 
symptom intensity of response [i.e., mild (1), 
moderate (2), and severe (3)] (Milian et al. 
2007); the mean difference in the prebeach 
walk and postbeach walk symptom scores was 
then evaluated for each individual.
As with the symptoms, each participant 
served as their own spirometry control. We 
present the mean difference of the individual 
pre  beach walk minus post  beach walk spirom-
etry values. A positive mean difference indi-
cated a decrease in lung function after the walk 
compared with before the walk. Because bre-
vetoxins were meas  ured ≥ 1 mile inshore from 
the coast during active K. brevis bloom aerosols 
when there were strong-enough onshore winds, 
“coastal residence” was defined as residence on 
a barrier island or along Sarasota Bay within 
1 mile of a coast (Kirkpatrick et al. 2006). As in 
previous studies, the use of asthma medications 
within 12 hr before going to the beach was 
used as a surrogate for increased asthma sever-
ity (Fleming et al. 2007; Milian et al. 2007).
Statistics. We created the study data-
base in Microsoft ACCESS (Microsoft 
Corporation, Redmond, WA), with direct 
data entry during participant interviews. 
Descriptive and other statistical analyses were 
performed using SAS statistical software, ver-
sion 9.1 (SAS Institute Inc., Cary, NC). For 
all subjects who participated in both March 
2005 and September 2006, we used the data 
with the highest LC-MS ambient measure. 
For the symptom data, analyses were per-
formed using the distribution of the exposure 
measures by quartiles and by above/below the 
median of the ambient brevetoxin level. For 
pulmonary function data, we compared the 
mean differences between the different groups 
above and below the mean, the median, and 
by quartiles, depending on the particular data 
distribution. Statistical hypothesis testing was 
performed using paired t-test for continu-
ous data and McNemar’s test for categorical 
data to compare pre  beach and post  beach data 
(Kleinbaum et al. 1982). The McNemar’s 
test at 0.05 level of significance uses only the 
data on the diagonal of the two-by-two table, 
which indicates a change; thus, subjects who 
came to the beach reporting no symptom and 
left reporting a particular symptom were com-
pared with subjects who came to the beach 
reporting a symptom and left reporting no 
particular symptom. For the symptom score, 
the pre  beach walk value of each individual 
was compared with that individual’s post-
beach walk value using a two-tailed paired 
t-test at the 0.05 level of significance. In 
addition, we performed correlation analyses 
between individual pulmonary function tests 
(PFTs) and the ambient measures, as well 
as multi  variable regression analysis with dif-
ferences between pre- and post-PFTs (as the 
outcome variable), ambient levels, medication 
use, sex, age, and geographic proximity of 
residence to the coast.
Results
There were 87 asthmatic persons ≥ 12 years of 
age who participated in at least one exposed 
study period during 2005–2006, with a mean 
age (± SD) of 44.9 ± 19.2 (range, 12.0–79.0) 
(Table 1). The majority (56%) were white, 
non-Hispanic females with many years of 
asthma diagnosis.
Ambient exposure. Although there were 
nine sampling periods from 2003 through 
2008, which included 3 exposed days (March 
2003, March 2005, September 2006) and 
6 unexposed days (January 2003, May 
2004, October 2004, February 2005, June 
2007, September 2007, May 2008), we used 
the exposure days from March 2005 and 
September 2006 because the aerosol sampling 
equipment and analyses had been optimized 
in terms of air sampler flow rates and limits 
of detection for the brevetoxins (Table 2). 
Of note, the Florida red tide had been pres-
ent in both cases in the Sarasota area for 
about 1–2 months before the study periods; 
the range of brevetoxins measured for these 
two study periods was only exceeded in one 
prior study with a peak brevetoxin level of 
93 ng/m3 measured by HPLC (Backer et al. 
2003; Fleming et al. 2007).
We found strong and statistically signifi-
cant correlations among the personal ELISA, 
the ambient ELISA, and the ambient LC-MS. 
In particular, the personal ELISA and the 
hourly ambient ELISA had a correlation coef-
ficient of 0.71 (p < 0.001), as did the per-
sonal ELISA and the hourly ambient LC-MS 
(r = 0.71; p < 0.001), whereas the ambient 
ELISA and LC-MS measurements were even 
more highly correlated (r = 0.91; p < 0.001).
Ambient exposure and human health. 
Among the 87 people with a personal 
sample ELISA, the mean (± SD) level 
was 73.3 ± 78.9 ng/m3, with a range of 
0–366.2 ng/m3 and a median of 45.7 ng/m3. 
For the ambient hourly sample ELISA, the 
mean level was 161.5 ± 96.3 ng/m3, with 
a range of 0–375.4 ng/m3 and a median of 
141.0 ng/m3. For the ambient hourly sample 
LC-MS, the mean level was 53.4 ± 32.9 ng/m3, 
with a range of 0–117.5 ng/m3 and a median of 
56.8 ng/m3. 
Upon review, the hourly ambient LC-MS 
measurements had the strongest associations 
with the health end points (i.e., symptoms and 
pulmonary functions); therefore, only the asso-
ciations between the hourly LC-MS ambient 
measurements of aerosolized breve  toxins and 
the health end points are summarized below. 
Report of symptoms. Symptoms yes/no. 
For the individuals having an hourly ambient 
LC-MS brevetoxin level above the median 
Table 2. Summary of ambient data during exposed study periods: K. brevis cell counts, total brevetoxins in water, and from high-volume and personal air samplers.
              High-volume air:   Personal air:
      Wind  Wind direction  Range of  Water: range of  total brevetoxins  average TWA
  Temperature (°C)  Humidity (%)  speed (mph)  index  K. brevis in water  total brevetoxins  (ng/m3)  (ng/m3)
Date  (mean ± SD)  (mean ± SD)  (mean ± SD)  (mean ± SD)  (cells/L)a  (µg/L)b  (mean ± SD)c  (mean ± SD)d
2005
11 Mar  18.8 ± 0.4  72 ± 3  6.1 ± 3.3  0.76 ± 0.18  54,000–200,000  2.25–11.95  39.0 ± 13.0  41.4 ± 24.7
12 Mar  18.7 ± 0.8  34 ± 7  6.1 ± 1.8  0.50 ± 0.40      27.8 ± 11.6  77.5 ± 49.2
13 Mar  20.0 ± 0.4  89 ± 2  9.5 ± 1.4  0.51 ± 0.10      21.2 ± 6.9  26.1 ± 19.5
14 Mar  20.6 ± 0.2  95 ± 1  7.6 ± 1.5  0.40 ± 0.09      22.3 ± 13.3  18.5 ± 14.2
2006
22 Sep  29.5 ± 0.5  72 ± 2  9.3 ± 2.5  0.52 ± 0.35  694,000–4,280,000  16.69–69.26  46.7 ± 13.7  68.1 ± 64.2
23 Sep  33.3 ± 1.4  48 ± 7  5.5 ± 1.4  0.23 ± 0.29      58.7 ± 31.0  68.2 ± 97.1
24 Sep  32.6 ± 1.4  57 ± 6  6.3 ± 1.2  0.84 ± 0.17      74.7 ± 25.1  156.0 ± 90.4
TWA, time-weighted average. 
aLOD of K. brevis = 1,000 cells/L. bLOD of PbTx water = 0.03 µg/L. cHigh-volume air sampler measured by LC-MS; LOD = 0.01 ng/m3. dPersonal air sampler meas  ured by ELISA; LOD = 
0.6 ng/sample.Fleming et al.
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(i.e., 56.8 ng/m3), statistically significant dif-
ferences for upper and lower respiratory tract 
symptoms (i.e., cough, wheeze, throat irri-
tation, chest tightness, and nasal irritation) 
were seen when examining the change from 
“no symptom” before beach exposure to “yes 
symptom” after beach exposure (Table 3). For 
below the median, there was only a significant 
report of chest tightness.
We also observed statistically signifi-
cant differences for both above and below 
the median brevetoxin level for those with-
out medications within 12 hr of going to 
the beach (no medications). Those who lived 
≥ 1 mile from the coast (far) had significant 
reports for all respiratory symptoms (data not 
shown). For those who lived close to the coast 
or reported using medications, only report of 
cough and chest tightness were significantly 
increased above the median.
We observed statistically significant differ-
ences in the asthmatics in the highest exposure 
quartile of hourly ambient LC-MS brevetoxin 
level compared with those in the lowest expo-
sure quartile with respect to the seven respira-
tory symptoms (Table 3). Overall, those in the 
highest exposure quartile reported significantly 
more respiratory symptoms than those in the 
lowest exposure quartile. 
Symptom scores. For the hourly ambi-
ent LC-MS brevetoxin level, the difference 
in the mean symptom scores pre- and post-
exposure above the median brevetoxin level 
were statistically significant (Table 4). For 
below the median, we found no significant 
differences in the mean pre/post  exposure 
respiratory symptom scores. In addition, the 
mean differences in the symptom scores were 
increased for the hourly ambient LC-MS 
above the median compared with those below 
the median (mean ± SD: 4.14 ± 3.46 vs. 0.32 
± 3.51, respectively). 
We found statistically significant differ-
ences above the median brevetoxin level for the 
mean difference in the pre/post  exposure respi-
ratory symptom for those both with and with-
out medications within 12 hr of going to the 
beach (Table 4). For below the median, there 
were no significant differences in the mean 
pre/post  exposure respiratory symptom scores. 
The mean differences in the symptom scores 
were increased above the median brevetoxin 
level compared with those below the median 
(no medications: 3.89 ± 2.97 vs. 1.35 ± 3.86, 
respectively; with medications: 5.11 ± 5.06 vs. 
0.67 ± 3.01, respectively). We also observed 
statistically significant differences above the 
median for the mean difference in the pre/
post  exposure respiratory symptom scores for 
those with those who lived > 1 mile (far) and 
≤ 1 mile (close) from the coast (Table 4). For 
below the median, there were no significant 
differences in the mean pre/post  exposure 
respiratory symptom scores. The mean differ-
ences in the symptom scores were increased 
above the median brevetoxin level compared 
with those below the median (far: 4.44 ± 3.71 
vs. 0.64 ± 3.03, respectively; close: 2.89 ± 2.32 
vs. 0.06 ± 4.12, respectively).
PFTs. None of the comparisons between 
the differences in the means above and below 
the median for the personal ELISA, or the 
hourly ambient ELISA and LC-MS brevetoxin 
levels were statistically significant (Table 5; 
data are shown only for the hourly ambient 
LC-MS). We found considerable variation in 
the pulmonary function data, and not all the 
mean differences were positive (i.e., demon-
strating decreased pulmonary function after 
exposure compared with before). Only the 
personal ELISA PFT results demonstrated a 
consistent pattern where the above-the-median 
pulmonary function differences were greater 
than the below-the-median pulmonary func-
tion differences (data not shown).
The correlations between the pre/post-
exposure pulmonary function differences for 
each individual pulmonary function meas-
ures with the personal ELISA and the hourly 
ambient ELISA and LC-MS brevetoxin lev-
els were negative (i.e., as the measured bre-
vetoxin level increased, the difference in 
individual pulmonary functions decreased); 
however, these results were non  significant 
and very small, ranging from r = –0.04 to 
–0.14 (data not shown). Finally, using mul-
tiple regression with pre/postexposure FEV1 
score as the outcome measure predicted by 
the model of ambient level, asthma medica-
tion use, sex, age, and proximity, we found no 
significant results. The very small R2 (0.008) 
indicated that < 1% of the variation in mean 
pre/postexposure FEV1 score difference could 
be accounted for by these variables (data not 
shown).
Discussion
In this study we examined the possible dose–
response relationship between health effects 
(i.e., reported symptoms and PFT results) and 
exposure to brevetoxins measured during 1 hr 
of exposure to Florida red tide aerosols (i.e., 
by the personal ELISA and the hourly ambi-
ent ELISA and LC-MS). We found strong 
associations between the two ambient and one 
personal sampler brevetoxin meas  ures. There 
was a statistically significant and positive dose–
response relationship between reported asthma 
symptoms with all the ambient measures, 
particularly with the ambient LC-MS, for 
brevetoxin aerosols > 57 ng/m3 (the median 
brevetoxin level as measured by LC-MS 
from the hourly ambient sampler). We also 
observed an association between report of 
asthma symptoms for persons with less-severe 
asthma (i.e., not on medications) and persons 
who lived > 1 mile from the coast, but with-
out a dose–response relation  ship, as measured 
by the hourly ambient LC-MS. No associa-
tion was found between pulmonary function 
changes and the three brevetoxin measures 
using various methods of data analy  sis, nor 
was any dose–response relationship apparent.
The finding of a greater association between 
report of symptoms and the ambient LC-MS 
monitoring as opposed to the personal and 
ambient ELISA monitoring for brevetoxins is 
not unexpected. The ELISA measures many 
components of the brevetoxin structure, includ-
ing a recently discovered compound, brevenal, 
that has been found to be a natural antagonist 
Table 3. Comparisons between, above, and below the median, and between the highest 25th percentile and the lowest 25th percentile of the brevetoxin level as 
measured by the ambient LC-MS by pre/postexposure symptoms (n = 87).
  Ambient LC-MS brevetoxin level: median  Ambient LC-MS brevetoxin level: percentile
  Overall (n = 87)  Below median  Above median  Lowest 25th percentile  Highest 25th percentile
Symptoms  Pre/post (n)a  p-Valueb  Pre/post (n)a  p-Valueb  Pre/post (n)a  p-Valueb  Pre/post (n)a  p-Valueb  Pre/post (n) a  p-Valueb
Cough  41  0.0001  11  0.13  30  0.0001  5  0.26  15  0.0001
Wheezing  17  0.01  2  0.26  15  0.0001  1  0.56  6  0.01
Throat irritation  34  0.0001  12  0.37  22  0.0001  4  0.41  13  0.0003
Shortness of breath  21  0.02  5  0.56  16  0.0003  3  1.00  9  0.01
Chest tightness  28  0.0001  12  0.02  16  0.0003  6  0.16  7  0.03
Nasal irritation  28  0.02  11  0.84  17  0.0002  8  0.80  8  0.02
Eye irritation  11  0.23  3  0.71  8  0.058  3  0.32  3  0.93
Headache  16  0.10  8  0.59  8  0.058  3  1.00  3  0.66
Itchy skin  7  0.37  2  0.41  5  0.03  1  0.56  2  0.16
Diarrhea  0  —  0  —  0  —  0  —  0  —
Other  6  0.16  3  0.66  3  0.08  3  0.32  2  —
aPersons who came to the beach with no symptom and left with a symptom. bEvaluated by McNemar’s test. Asthma and brevetoxin exposure
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to breve  toxins (Abraham et al. 2005a, 2005b; 
Bourdelais et al. 2004; Naar et al. 2002). The 
LC-MS is specific for individual brevetoxins, 
particularly brevetoxin 2 and 3 (PbTx-2 and 
PbTx-3, respectively); these brevetoxins have 
been associated with the most significant respi-
ratory effects in asthmatic sheep and other ani-
mal models (Abraham et al. 2005a, 2005b; 
Benson et al. 2005). In the future, we plan to 
measure brevetoxins using both the ELISA 
and LC-MS for the personal samplers because 
the personal samplers should more accurately 
capture the breathing zone of the individual 
compared with the ambient monitors.
In the present study we were able to detect 
significant differences and a dose–response 
relationship for the reported symptoms, but 
not for the PFTs. As pointed out by Stemple 
and Fuhlbrigge (2008), a major limitation in 
the interpretation of all asthma literature is the 
inconsistency in the definition of response to 
pulmonary function testing. They concluded 
that response must be defined as a combina-
tion of self-report of symptoms and objective 
measures (such as PFTs). To address this issue, 
in future studies we will include more precise 
measures of asthma severity as part of the pre-
exposure health assessment, as well as assessment 
of exhaled condensates for inflammatory mark-
ers. Of note, in prior studies of very healthy 
lifeguards and general recreational beach goers 
exposed to Florida red tide aerosols, signifi  cant 
differences were detected only in the reported 
symptoms, not in the PFTs (Backer et al. 2003, 
2005). Based on prior research on the particu-
late size of the Florida red tide aerosol, 75–85% 
of the aerosol remains in the nasal passages and 
does not reach the lung (Cheng et al. 2005a, 
2005b, 2005c). Furthermore, based on data 
from the sheep model of asthma and Florida 
red tide, it appears that the 1-hr exposure on 
the beach to brevetoxins in aerosols of Florida 
red tide for the asthmatic study subjects may 
represent a relatively low exposure level at a 
value near the toxicity threshold (Abraham W, 
personal communication).
In the present study, the subjects ideally 
performed their pulmonary function testing as 
soon as they returned from their 1 hr of beach 
exposure, but it is possible that because of 
inadvertent delays in testing, air conditioning 
of the study testing vehicle, or use of asthma 
medication, any true changes in pulmonary 
function were not detected. Furthermore, it 
is also possible in some cases that detectable 
pulmonary function changes were delayed 
by hours or even days, and were thus not 
detected by immediate PFTs. Of note, these 
asthmatic subjects have reported symptoms 
lasting up to at least 5 days after from their 
1 hr study exposure (Kirkpatrick et al. 2009). 
In addition, Kirkpatrick et al. (2006) reported 
increases in emergency room admissions for 
asthma, pneumonia, and bronchitis noted 
in coastal residents during active Florida red 
tides. Finally, it is also possible that the sam-
ple size of the asthmatic participants was not 
large enough to address the very large variabil-
ity in the pulmonary function testing results 
typically seen in asthmatics.
In a previous study (Fleming et al. 2007) 
we noted that symptom scores were signifi-
cantly higher for study participants reporting 
no use of asthma medications in the 12 hr 
prior to the study exposure (used as a surrogate 
measure of less-severe asthma) after the 1 hr of 
study exposure. This was also observed in the 
present analysis, but without a dose–response 
relationship to brevetoxin exposure measure-
ment. Both coastal and inland residents have 
been shown to report an increased symptom 
score after 1 hr of study exposure in a previous 
study based on symptom score (Milian et al. 
2007). In that analysis, only inland residents 
had a significant report of asthmatic symp-
toms, again without a dose–response relation-
ship to brevetoxin exposure measurement. The 
lack of dose–response relationship may mean 
that asthmatics without medications or who 
have not had recent ambient red tide expo-
sure because of living inland are more sensitive 
to the effects of brevetoxins than those using 
medications and living in coastal areas with 
constant ambient exposure. Data from the 
sheep model and Florida red tide indicate that 
the medications commonly used in asthma 
management mitigate the effects of the toxins 
(Abraham et al. 2005a, 2005b).
Another possible limitation to the present 
study is the reliance on self-reported data for 
the symptoms. However, despite variable reli-
ability (Chen et al. 2006; Martinez-Moragon 
et al. 2006), self-report of symptoms is one of 
the cornerstones of asthmatic diagnosis and 
clinical care (Stemple and Fuhlbrigge 2008). 
Of note, an important strength of the present 
study was the comparison of each individual 
with themselves, decreasing the possible effects 
of individual confounders (such as smoking, 
obesity, and work environment). The study 
participants (and researchers) have no way of 
knowing the amount (or even presence) of 
exposure they received at the time of beach 
exposure or during the post  exposure ques-
tionnaire administration, as the brevetoxin 
analytical results are not received for many 
days after the field study has been completed.
Conclusions 
In previous studies, we demonstrated statisti-
cally significant changes in reported symp-
toms for lifeguards, general beach goers, and 
asthmatics, as well as statistically significant 
changes in PFTs in asthmatics, after exposure 
to breve  toxins in Florida red tide aerosols. 
In the present study we explored the use of 
intensive ambient and personal air monitor-
ing in the characterization of these exposures 
and their possible relationship to health 
effects in the asthmatic study population. We 
found that hourly ambient air monitoring 
for brevetoxins as measured by LC-MS was 
strongly associated with symptom report. Our 
results suggest that self-reported symptoms 
are a valuable measure of the extent of health 
effects from exposure to aerosolized breve-
toxins in asthmatic populations. After only 
1 hr of exposure to brevetoxins in Florida red 
tide aerosols, the asthmatics had statistically 
significant changes in their reported respira-
tory symptoms and symptom scores for bre-
vetoxin aerosols > 57 ng/m3 (as measured by 
LC-MS). Significant increases in self-reported 
symptoms were also observed for those not 
using medications and those living ≥ 1 mile 
from the coast. These associations were not 
seen with the pulmonary function testing. 
This lack of association between brevetoxin 
exposure and PFT results may represent 
Table 5. PFT mean differences pre- and post-
exposure above and below the median brevetoxin 
level as measured by ambient LC-MS (n = 87).
      PFT    
     difference (mL)
PFT  Exposure level  (mean ± SD)  p-Valuea
FEV1  Above median  27.3 ± 123.0  0.62
  Below median  39.8 ± 113.8
FVC  Above median  10.0 ± 128.5  0.10
  Below median  61.4 ± 159.4
FEF25–75  Above median  –22.3 ± 333.97  0.32
  Below median  40.2 ± 234.9
PEF  Above median  224.3 ± 500.1  0.95
  Below median  217.9 ± 560.2
aEvaluated by t-test of difference in mean differences.
Table 4. Pre/postexposure mean difference in respiratory symptom score above and below the median 
brevetoxin level measured by the hourly ambient LC-MS (n = 87).
  Below median  Above median
  Pre/postexposure    Pre/postexposure 
  mean difference in    mean difference in
  symptom score ( ± SD) p -Valuea  symptom score ( ± SD) p -Valuea
All participants  0.32 ± 3.51  0.57  4.14 ± 3.46  0.0001
Used asthma medications within 12 hr before study exposure
  Yes  0.67 ± 3.10  0.34  5.11 ± 5.06  0.02
  No  1.35 ± 3.68  0.11  3.89 ± 2.97  0.0001
Distance of residence from coast
  Close (≤ 1 mile)   0.06 ± 4.12  0.95  2.89 ± 2.32  0.006
  Far (> 1 mile)   0.64 ± 3.03  0.33  4.44 ± 3.71  0.0001
aEvaluated by paired t-test. Fleming et al.
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insensitivity or timing issues of the pulmo-
nary function measurements and/or exposure 
to brevetoxins near the threshold of toxicity, 
both of which will be explored in the future. 
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